64th ASH Annual Meeting and Exposition: Are higher factor levels a rising consideration when selecting a hemophilia treatment?

-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member

denotes an abstract that is clinically relevant.

denotes that this is a recommended PHD Trainee Session.

denotes that this is a ticketed session.

Are higher factor levels a rising consideration when selecting a hemophilia treatment?

Sponsor: Novo Nordisk

Product Theaters

Hall J - Theater 6 (Ernest N. Morial Convention Center)

Speakers:

Stephanie Valer Seremetis, MD, Novo Nordisk and Adam R. Wufsus, PhD, Novo Nordisk

Disclosures:

No relevant conflicts of interest to declare.

For in-person participants only

See more of: Product Theaters